Wave Life Sciences
WVE· Manufacturing· Fiscal year ends in December
Paul B. Bolno is the CEO of Wave Life Sciences and was paid $2.7M in FY2022 (Dec).
Executives4
See all- 1Paul B. BolnoPresident and Chief Executive OfficerFY2022
- 2Kyle Moran, CFAChief Financial OfficerFY2024
- 3Christopher Francis, Ph.D.Senior Vice President, Corporate Development and Head of Emerging AreasFY2023
- 4Chandra Vargeese, Ph.D.Chief Technology Officer, Head of Platform Discovery SciencesFY2022
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allWave Life Sciences paid its one named executive on file $1.9M in FY2024 (Dec).
| Name | |||
|---|---|---|---|
| Kyle Moran, CFAChief Financial Officer | |||
| Paul B. BolnoPresident and Chief Executive Officer | Not disclosed | Not disclosed | |
| Christopher Francis, Ph.D.Senior Vice President, Corporate Development and Head of Emerging Areas | Not disclosed | ||
| Chandra Vargeese, Ph.D.Chief Technology Officer, Head of Platform Discovery Sciences | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers15
See allThe FY2024 (Dec) proxy of Wave Life Sciences names 15 peer companies for pay. Among Wave Life Sciences and these peers, CEO pay was the lowest of 7 and total shareholder return was the highest of 7.
7th highest of 7in Wave Life Sciences and its pay peers, FY2024 (Dec) by CEO pay:
1st highest of 7in Wave Life Sciences and its pay peers, FY2024 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Christian HenryChair · 8 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | May 7, 2026 | — |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Jun 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 4, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jun 21, 2024 | FY2023 |
| Annual report | 10-K | Mar 6, 2024 | FY2023 |